Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Investors Who Lost Money on Johnson & Johnson Should Contact Levi & Korsinsky About an Ongoing Investigation - JNJ
10:15am, Tuesday, 21'st Jan 2025
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to Connect
10:00am, Tuesday, 21'st Jan 2025
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Tuesday, 21'st Jan 2025
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
08:18am, Tuesday, 21'st Jan 2025
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The spray
US FDA approves J&J's ketamine-based therapy to treat depression
08:06am, Tuesday, 21'st Jan 2025
The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato, to treat adults with major depressive disorder, the company said on Tuesday.
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
08:00am, Tuesday, 21'st Jan 2025
Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compar
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
06:00am, Tuesday, 21'st Jan 2025
When most of us think of investing in stocks, we think of the potential gains -- or unfortunately, in some cases, losses -- that might follow. A particular stock will rise or fall, and we'll benefit o
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
05:34am, Tuesday, 21'st Jan 2025
2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average (^DJI 0.78%) had just a 12.9% return, compared to 23.3% for the S&P 500 (^GSPC 1.00%) and 28.6% for
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
04:17am, Tuesday, 21'st Jan 2025
Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with enterprise software sales or consumer goods, spending on healthcare tends
PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanopartic
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings?
04:11pm, Monday, 20'th Jan 2025
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. It remains to be seen if MedTech sales improved.
Johnson & Johnson (JNJ) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
11:00am, Monday, 20'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible
What Analysts Think of Johnson & Johnson Stock Ahead of Earnings
10:06am, Monday, 20'th Jan 2025
Johnson & Johnson (JNJ) is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from the same time last year.
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Stockholders to Inquire about Securities Investigation
10:00am, Monday, 20'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ
NEW YORK, NY / ACCESSWIRE / January 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible viol
